Trial Profile
Open Label Study to Evaluate Long Term Treatment Effect of DiaPep277® in Patients Who Have Completed Studies 461* (Phase II) or 901** (Pase III)
Status:
Completed
Phase of Trial:
Phase III
Latest Information Update: 03 Aug 2022
Price :
$35
*
At a glance
- Drugs Peptide p277 (Primary)
- Indications Type 1 diabetes mellitus
- Focus Registrational; Therapeutic Use
- Sponsors Andromeda Biotech
- 27 Jun 2016 New trial record